One integrated platform, from your therapeutic goal to high-quality mRNA, with scalability and supply security built into every step.
Who we are
Ternaria designs the quality layer for therapeutic mRNA. How an mRNA is designed and produced shapes how it performs in the body, from potency to safety to reproducibility.
RNA performance is shaped long before it reaches the cell. RNA polymerase purity, IVT performance and construct design work together to determine RNA quality, translation, potency and safety.
We bring RNA design, enzyme innovation, and production together. We develop and manufacture ultra-pure RNA polymerases and purpose-built mRNA, powered by our proprietary platform that enables the next generation of RNA technologies.
We work with teams pushing RNA further, from academic research and therapeutic development to pharma R&D, manufacturing partners and CDMOs, across vaccines, oncology and rare disease.
What we offer
The therapeutic outcome the mRNA must deliver
Optimal IVT reaction with proprietary enzymes
Optimal design and function
High-quality mRNA for any therapeutic application
Construct design and enzyme development for your programme, with Ternaria as your long-term partner.
Discuss a partnership →Custom mRNA to your specification, ArtPure™ polymerases and complete IVT kits.
Browse products →The evidence
Head-to-head vs. two leading suppliers
Higher is better
Head-to-head vs. two leading suppliers
Lower is better
EGFP mRNA, equal amounts injected


Human cells · zebrafish embryos · salmon eggs
From our customers
Products
Ultra-pure RNA polymerases produced via ArtPure™ technology. Available in glycerol and lyophilized formats for flexible in vitro transcription workflows.
View products
Complete kits for reproducible in vitro transcription — optimised buffers, nucleotides, and ArtPure™ enzymes in a single workflow.
View products
Ready-to-use mRNA products and custom synthesis to your sequence, modification, and scale requirements — produced with ArtPure™ enzymes.
View productsOur Team
Professor of Cell Biology, University of Iceland. PhD from Oxford University. Research focus on autophagy and cancer. Former Chair of the Icelandic Research Council and Chair of the Icelandic Research Infrastructure fund.
PhD in Biochemistry from Medical College of Virginia. Postdoc at SUNY Stony Brook. 30+ years in protein chemistry and assay development across US institutes and corporations.
Professor of Molecular Biology, University of Iceland. PhD from UCLA, postdoc at NIH. Expert in gene transcription and melanoma. Former Chair of European Molecular Biology Labs (EMBL).
Extensive pharma and medtech leadership. Former C-level at Kerecis during its growth to unicorn. MSc Pharmacy + MBA.
PhD in cell biology from University of Glasgow and postdoctoral training University of Iceland. Various positions at University of Iceland and EMBL, Heidelberg. Shareholder and board member in a German family company.
Doctorate in drug delivery from the University of Iceland. Background in genetic engineering, enzymatic activity, and vaccine R&D.
PhD and postdoctoral training from Cornell University. Research focus on RNA biology and mRNA translation at untranslated regions. Functional genomics experience at Decode Genetics.
MSc in Molecular Life Sciences from the University of Iceland. Experience in biochemical techniques across diverse cell models.
MSc in Molecular Life Sciences from the University of Iceland. Experience in biochemical techniques including advanced microscopy.
Get in touch
Whether you have questions about our products, want to discuss a partnership, or are interested in Ternaria as an investor — we'd love to hear from you.
Send us a message